⌘K

Home/Filings/4/0001179110-21-002694

4//SEC Filing

Chen Hongming 4

Accession 0001179110-21-002694

CIK 0001479419other

View on SEC.gov Company Profile

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 5:01 PM ET

Size

6.6 KB

Accession

0001179110-21-002694

Insider Transaction Report

Form 4

Period: 2021-03-01

Kala Pharmaceuticals, Inc.KALA

Chief Scientific Officer10% Owner

Transactions

Exercise/Conversion
Common Stock
2021-03-01$2.30/sh+9,500$21,850→ 243,015 total
Exercise/Conversion
Stock Option (right to buy
2021-03-01−9,500→ 53,736 total
Exercise: $2.30Exp: 2024-10-02→ Common Stock (9,500 underlying)

Footnotes (2)

[F1]Includes 99,666 unvested RSUs.
[F2]The option was fully vested.

Documents

1 file

4
edgar.xmlPrimary
FORM 4 -

Issuer

Kala Pharmaceuticals, Inc.

CIK 0001479419

Entity typeother

Related Parties

1

filerCIK 0001710697

Filing Metadata

Form type: 4
Filed: Mar 2, 7:00 PM ET
Accepted: Mar 3, 5:01 PM ET
Size: 6.6 KB

View on SEC.gov